Immunobiology of cholangiocarcinoma.
Immunosuppressive myeloid cells
immune evasion
immunogenic
preclinical models
Journal
Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
03
03
2023
revised:
18
04
2023
accepted:
03
05
2023
pmc-release:
01
09
2024
medline:
22
8
2023
pubmed:
19
5
2023
entrez:
18
5
2023
Statut:
ppublish
Résumé
Recent literature has significantly advanced our knowledge and understanding of the tumour immune microenvironment of cholangiocarcinoma. Detailed characterisation of the immune landscape has defined new patient subtypes. While not utilised in clinical practice yet, these novel classifications will help inform decisions regarding immunotherapeutic approaches. Suppressive immune cells, such as tumour-associated macrophages and myeloid-derived suppressor cells, form a barrier that shields tumour cells from immune surveillance. The presence of this immunosuppressive barrier in combination with a variety of immune escape mechanisms employed by tumour cells leads to poor tumour immunogenicity. Broad strategies to re-equip the immune system include blockade of suppressive immune cell recruitment to priming cytotoxic effector cells against tumour antigens. While immunotherapeutic strategies are gaining traction for the treatment of cholangiocarcinoma, there is a long road of discovery ahead in order to make meaningful contributions to patient therapy and survival.
Identifiants
pubmed: 37201670
pii: S0168-8278(23)00338-0
doi: 10.1016/j.jhep.2023.05.010
pmc: PMC10524996
mid: NIHMS1902602
pii:
doi:
Substances chimiques
Antigens, Neoplasm
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
867-875Subventions
Organisme : NCI NIH HHS
ID : K08 CA236874
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK084567
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA210964
Pays : United States
Informations de copyright
Copyright © 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Références
J Immunol. 2018 Jan 15;200(2):432-442
pubmed: 29311385
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Clin Cancer Res. 2022 Dec 15;28(24):5431-5439
pubmed: 36190545
Nat Genet. 2015 Sep;47(9):1003-10
pubmed: 26258846
Nature. 2006 May 11;441(7090):235-8
pubmed: 16648838
JCI Insight. 2017 Jan 12;2(1):e89140
pubmed: 28097229
Sci Rep. 2022 Apr 13;12(1):6154
pubmed: 35418130
Br J Cancer. 2018 Jan;118(2):171-180
pubmed: 29123259
Int J Cancer. 2020 Oct 15;147(8):2190-2198
pubmed: 32359091
Hepatology. 2022 Feb;75(2):297-308
pubmed: 34510503
Hepatology. 2021 Jan;73 Suppl 1:75-85
pubmed: 32500550
J Clin Invest. 2020 Oct 1;130(10):5380-5396
pubmed: 32663198
Nat Commun. 2022 Mar 28;13(1):1642
pubmed: 35347134
Nature. 2022 Dec;612(7938):141-147
pubmed: 36352227
Cell Death Dis. 2022 Jan 28;13(1):94
pubmed: 35091535
Lancet Oncol. 2021 Oct;22(10):1468-1482
pubmed: 34592180
Anticancer Res. 2017 Jun;37(6):3229-3237
pubmed: 28551669
Nat Rev Immunol. 2020 Mar;20(3):158-172
pubmed: 31811270
J Hepatol. 2021 May;74(5):1145-1154
pubmed: 33276030
Tumour Biol. 2014 Jun;35(6):5357-67
pubmed: 24549785
Hepatology. 2012 Jan;55(1):86-97
pubmed: 21898484
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588
pubmed: 32606456
Cancer Discov. 2022 Mar 1;12(3):812-835
pubmed: 34848557
J Hepatol. 2020 Nov;73(5):1118-1130
pubmed: 32505533
J Immunother Cancer. 2021 Dec;9(12):
pubmed: 34873013
Ann Surg Oncol. 2020 Feb;27(2):599-607
pubmed: 31407173
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33692217
Cancer Discov. 2021 May;11(5):1248-1267
pubmed: 33323397
J Hepatol. 2021 Apr;74(4):860-872
pubmed: 33221352
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Gut. 2022 Jul;71(7):1386-1398
pubmed: 34413131
Hepatobiliary Pancreat Dis Int. 2016 Feb;15(1):99-105
pubmed: 26818550
Nat Rev Clin Oncol. 2018 Feb;15(2):95-111
pubmed: 28994423
JHEP Rep. 2019 Jul 10;1(4):297-311
pubmed: 32039381
J Gastrointest Surg. 2019 Nov;23(11):2216-2224
pubmed: 30843133
J Hepatol. 2019 Oct;71(4):753-762
pubmed: 31195061
J Hepatol. 2022 Mar;76(3):608-618
pubmed: 34793865
J Clin Invest. 2015 Mar 2;125(3):1269-85
pubmed: 25689248
Transl Oncol. 2019 Feb;12(2):217-225
pubmed: 30415063
Nat Med. 2019 May;25(5):759-766
pubmed: 31036879
Sci Rep. 2021 Mar 18;11(1):6276
pubmed: 33737613
Cancer Sci. 2010 Aug;101(8):1913-9
pubmed: 20545696
Surgery. 2018 Sep;164(3):411-418
pubmed: 29903509
Hum Vaccin Immunother. 2020 Oct 2;16(10):2318-2327
pubmed: 31976810
J Immunother. 2021 Sep 1;44(7):254-263
pubmed: 34191790
Cell. 2016 Apr 21;165(3):668-78
pubmed: 27062926
Clin Med Res. 2005 Aug;3(3):166-75
pubmed: 16160071
Lancet Gastroenterol Hepatol. 2022 Jun;7(6):522-532
pubmed: 35278356
Hum Vaccin Immunother. 2018 Jun 3;14(6):1423-1431
pubmed: 29420117
Eur J Cancer. 2017 Nov;86:158-165
pubmed: 28988016
Cancer Immunol Res. 2017 Jan;5(1):3-8
pubmed: 28052991
Sci Rep. 2017 Oct 31;7(1):14419
pubmed: 29089545
Ann Surg Oncol. 2016 Aug;23(8):2610-7
pubmed: 27012989
Gut. 2023 Apr;72(4):736-748
pubmed: 35584893
Hepatology. 2020 Mar;71(3):893-906
pubmed: 31298745
Expert Opin Ther Targets. 2021 Oct;25(10):835-845
pubmed: 34806500
Hepatology. 2022 Jan;75(1):28-42
pubmed: 34387870
Nat Rev Immunol. 2023 Feb;23(2):90-105
pubmed: 35637393
Sci Transl Med. 2014 May 21;6(237):237ra67
pubmed: 24848257
Annu Rev Med. 2020 Jan 27;71:47-58
pubmed: 31412220
Cancer Cell. 2017 Jun 12;31(6):771-789.e6
pubmed: 28609656
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3270-5
pubmed: 11248068
Hepatology. 2022 Oct;76(4):982-999
pubmed: 35106794
Nat Immunol. 2022 May;23(5):660-670
pubmed: 35241833
Cancer Immunol Immunother. 2021 May;70(5):1451-1464
pubmed: 33180184
PeerJ. 2020 Jan 22;8:e8458
pubmed: 32002338
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Cancer Res. 2015 Nov 1;75(21):4441-5
pubmed: 26475869
Hepatology. 2020 Sep;72(3):965-981
pubmed: 31875970
J Hepatol. 2022 Nov;77(5):1359-1372
pubmed: 35738508
Immunity. 2017 Aug 15;47(2):374-388.e6
pubmed: 28813662
Dig Dis Sci. 2020 Oct;65(10):2937-2948
pubmed: 31853779
Nat Rev Dis Primers. 2021 Sep 9;7(1):65
pubmed: 34504109
Sci Rep. 2020 Nov 2;10(1):18848
pubmed: 33139767
Hepatology. 2008 Jan;47(1):90-6
pubmed: 18023027
Hepatol Commun. 2022 Jan;6(1):194-208
pubmed: 34558839
Gastroenterology. 2019 Oct;157(4):1067-1080.e9
pubmed: 31229495
Nat Rev Clin Oncol. 2022 Jun;19(6):402-421
pubmed: 35354979
Cancer Immunol Immunother. 2014 Mar;63(3):247-57
pubmed: 24357148
EBioMedicine. 2021 May;67:103375
pubmed: 33993051
Nat Rev Cancer. 2016 Jul;16(7):431-46
pubmed: 27282249
PLoS One. 2019 Dec 2;14(12):e0225327
pubmed: 31790437